Sanofi and Regeneron Pharmaceuticals, Inc.'s Libtayo was a late entrant in the saturated checkpoint inhibitor market and sales to date have been negligible but more promising late-stage data evaluating the drug in cervical cancer suggests the partners could carve out a lucrative niche in that less competitive indication.
Cervical Cancer Data Inject Fresh Life Into Sanofi's Libtayo
More Positive Phase III Findings For Regeneron-Partnered PD-1 Inhibitor
Libtayo is the first immunotherapy to demonstrate an improvement in OS, PFS and ORR in advanced cervical cancer and approval in this indication could kickstart its lackluster sales to date.
More from Immuno-oncology
More from Anticancer
• By
Merck expects Keytruda to come under Medicare price controls in 2028, but an analyst said the subcutaneous version could shield revenues for the franchise.
• By
J&J is confident that its bispecific antibody/kinase inhibitor combo’s overall survival win over AstraZeneca’s single-agent pill will shift the standard of care.
• By
The Danish firm is spending nearly $580m to repurchase up to 2.2 million shares